Abstract | OBJECTIVE: METHODS: All patients had received aspirin (100 mg/day) or no aspirin. BP subgroups were defined as low (average SBP from the baseline to the year of the events <130 mmHg), moderate (≥130 and <140 mmHg), and high (≥140 mmHg). The mean duration of follow-up was 5.02 years. RESULTS: In hypertensive patients (n = 12 278) aspirin had no significant impact on the primary outcome of death from cardiovascular disease, nonfatal stroke, and nonfatal myocardial infarction. On the other hand, aspirin increased the incidence of serious extracranial hemorrhage [hazard ratio, 1.81; 95% confidence interval (CI), 1.18-2.77; P = 0.0064] and tended to increase hemorrhagic stroke (hazard ratio, 1.75; CI, 0.99-3.07; P = 0.053). Aspirin had no effect on the primary outcome in any of the BP subgroups, and was associated with increased hemorrhagic stroke in the high BP group (hazard ratio, 3.51; CI, 1.29-9.51; P = 0.014); serious extracranial hemorrhage was elevated or tended to elevate in the moderate (hazard ratio, 2.53; CI, 1.18-5.45; P = 0.017) and high (hazard ratio, 2.14; CI, 1.00-4.56; P = 0.050) BP groups. CONCLUSION: In aged Japanese hypertensive patients, these data demonstrated no overall benefit of low-dose aspirin therapy although treatment was associated with an elevated risk of hemorrhagic events.
|
Authors | Katsuyuki Ando, Kazuyuki Shimada, Tsutomu Yamazaki, Shinichiro Uchiyama, Yukari Uemura, Naoki Ishizuka, Tamio Teramoto, Shinichi Oikawa, Masahiro Sugawara, Mitsuru Murata, Kenji Yokoyama, Yasuo Ikeda, Japanese Primary Prevention Project (JPPP) Study Group |
Journal | Journal of hypertension
(J Hypertens)
Vol. 37
Issue 6
Pg. 1301-1307
(06 2019)
ISSN: 1473-5598 [Electronic] Netherlands |
PMID | 31022110
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Aspirin
|
Topics |
- Aged
- Aged, 80 and over
- Aspirin
(therapeutic use)
- Blood Pressure
- Diabetes Mellitus
- Dyslipidemias
(complications)
- Female
- Hemorrhage
(chemically induced)
- Humans
- Hypertension
(complications)
- Intracranial Hemorrhages
(chemically induced)
- Male
- Middle Aged
- Myocardial Infarction
(prevention & control)
- Platelet Aggregation Inhibitors
(therapeutic use)
- Primary Prevention
- Stroke
(prevention & control)
- Treatment Outcome
|